Part of a new white paper series from PPD

"Considerations for the Design and Conduct of Clinical Trials for Hepatitis C" explores the nuances of the hepatitis C virus (HCV) that continue to impact the treatment strategies for the disease. PPD experts take a detailed look at the disease and break down the elements of a successful HCV study, including:

• Realistic startup timelines
• Country-specific requirements
• Patient populations, retention and follow-up
• Protocol designs that support efficient study development

Learn more about PPD’s HCV and infectious
disease expertise or contact us to share your
feedback.